Preparation method of medical composition containing polyglutamic acid, medical composition and medical dressing

Abstract

The present invention relates to the technical field of medical devices, and discloses a preparation method of a medical composition containing polyglutamic acid, a medical composition and a medical dressing. The medical composition containing polyglutamic acid includes, by mass percentage: sodium hyaluronate: 0.1% - 5%, glycerol: 2% - 6%, carbomer: 0.35% - 0.8%, hydroxyethyl cellulose: 0.3% - 3.5%, polyglutamic acid: 0.1% - 5%, trehalose: 1.8% - 2.5%, recombinant human collagen: 0.1% - 1%, β-glucan: 0.5% - 5.0%, silicon nitride particles: 0.5% - 1.5%, benzyl alcohol: 0.5% - 1.0%, and the balance is purified water. The medical composition containing polyglutamic acid can promote wound healing, inhibit melanin formation, whiten the skin, reduce pain and scar formation.

Description

Technical Field

[0001] The present invention relates to the technical field of medical devices, and provides a preparation method of a medical composition containing polyglutamic acid, a medical composition and a medical dressing. Background Art

[0002] With the popularization of biomedical materials and the increasing requirements of people for medical products, the function of medical dressings has developed from simple wound coverage to bioactive materials with complex functions. An ideal medical dressing should not only provide physical protection for the wound to prevent infection, but also promote wound healing, reduce pain and scar formation.

[0003] However, the existing medical dressings have limited wound healing effects, and unstable dressings may degrade or change in structure during storage, thereby affecting their functions and safety. Therefore, there is an urgent need for improvement. Summary of the Invention

[0004] The present invention provides a preparation method of a medical composition. The prepared medical composition has painlessness, mild whitening effect, low infection risk, high stability, convenient use, etc. The medical composition or medical dressing in the present invention can promote wound healing, inhibit melanin formation, whiten, reduce pain and scar formation.

[0005] The technical problems solved by the present invention are realized by the following technical solutions:

[0006] In a first aspect, the present application provides a preparation method of a medical composition containing polyglutamic acid. The method includes:

[0007] Providing a first solution containing purified water, glycerol and carbomer;

[0008] Mixing hydroxyethyl cellulose, polyglutamic acid, trehalose, silicon nitride particles with the first solution under heating conditions to obtain a third mixture;

[0009] Performing at least three ultrasonic treatments and cooling on the third mixture to obtain a fourth mixed solution;

[0010] Providing a second solution containing purified water, recombinant human collagen, sodium hyaluronate, β-glucan and benzyl alcohol;

[0011] Mix the fourth mixture with the second solution to obtain a medical composition, which, by mass percentage, comprises: sodium hyaluronate: 0.1% - 5%, glycerol: 2% - 6%, carbomer: 0.35% - 0.8%, hydroxyethyl cellulose: 0.3% - 3.5%, polyglutamic acid: 0.1% - 5%, trehalose: 1.8% - 2.5%, recombinant human collagen: 0.1% - 1%, benzyl alcohol: 0.5% - 1.0%, β-glucan: 0.5% - 5.0%, silicon nitride particles: 0.5% - 1.5%, and the balance is purified water.

[0012] In some embodiments, the medical composition, by mass percentage, comprises: sodium hyaluronate: 4%, glycerol: 4%, carbomer: 0.6%, hydroxyethyl cellulose: 3.5%, polyglutamic acid: 5%, benzyl alcohol: 0.8%, trehalose: 2.0%, recombinant human collagen: 1.0%, β-glucan: 4.0%, silicon nitride particles: 1.0%, and the balance is purified water.

[0013] In some embodiments, the mass ratio of the fourth mixture to the second solution is 1:(0.5 - 2).

[0014] In some embodiments, the mass ratio of polyglutamic acid, β-glucan and silicon nitride particles is 5:4:(0.8 - 1).

[0015] In some embodiments, the medical composition is solvent-based.

[0016] In some embodiments, at least three ultrasonic treatments sequentially include: the first ultrasonic treatment, the second ultrasonic treatment and the third ultrasonic treatment; the temperature of the first ultrasonic treatment is 40 - 50°C, and ultrasonic dispersion and emulsification are carried out at a frequency of 30 - 50 kHz for 1 - 3 min; the temperature of the second ultrasonic treatment is 50 - 60°C, and ultrasonic dispersion and emulsification are carried out at a frequency of 20 - 25 kHz for 2 - 5 min; the temperature of the third ultrasonic treatment is 50 - 65°C, and ultrasonic dispersion and emulsification are carried out at a frequency of 10 - 15 kHz for 2 - 5 min.

[0017] In some embodiments, subject the third mixture to at least three ultrasonic treatments and cooling to obtain a fourth mixture, including:

[0018] Subject the third mixture to at least three ultrasonic treatments, then turn on the vacuum for defoaming, and the defoaming time is 3 - 10 min;

[0019] Then cool down to 25 - 30°C to obtain the fourth mixture.

[0020] In some embodiments, the viscosity of the fourth mixture is 100 - 600 cst.

[0021] In a second aspect, the present application provides a medical composition containing polyglutamic acid, which is prepared by the preparation method of the first aspect.

[0022] In a third aspect, the present application provides a medical dressing, which is prepared by drying the medical composition prepared by the preparation method of the first aspect. The medical dressing is in a gel state, and the water content of the medical dressing is 40%-60%.

[0023] In the embodiments of the present application, polyglutamic acid is a natural biopolymer material produced by microbial fermentation, which has excellent biocompatibility, biodegradability, moisturizing and antibacterial effects; silicon nitride particles have excellent biocompatibility and safety in the medical composition, and at the same time have good antibacterial properties and biological activities; silicon nitride particles have physical pores, which can reduce the probability of inflammation. Benzyl alcohol is a compound with weak antibacterial properties, which can inhibit the growth of bacteria to a certain extent, reduce the risk of wound infection, and act with recombinant human collagen and β-glucan to promote wound healing and tissue repair. Benzyl alcohol is usually used as a solvent to help dissolve and stabilize other whitening active ingredients, such as human collagen and β-glucan. The medical composition can directly transfer polyglutamic acid and silicon nitride particles through the skin to the target area, such as the wound infection site, and it can provide a continuous and stable release. This continuous release method can avoid the blood drug concentration fluctuation caused by oral drugs, and is helpful to maintain a more stable healing effect. The medical dressing is easy to use and does not require oral administration, which improves patient compliance.

[0024] The medical dressing of the present application has high water content, softness and good biocompatibility, which greatly improves the acceptance of patients and has good healing effects.

[0025] In the preparation method of the present application, under the action of at least three ultrasonic treatments, the original molecular chains and hydrogen bond structures in the system can be broken up, and carboxyl groups and other groups in high molecular polymers such as carbomer can be promoted to combine with water and glycerol to form hydrogen bonds. The force generated by the hydrogen bonds will cause the coiled high molecular chains to unwind in the aqueous solution. Coating on the skin surface (coating in a solvent state) or coating on the skin surface after drying (coating in a gel state) can form a stable hydrogel network, thereby locking in moisture and enhancing the water retention effect of the composition. Description of the Drawings

[0026] In order to more clearly illustrate the technical solutions of the embodiments of the present application, the drawings required to be used in the embodiments of the present application will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present application. For those of ordinary skill in the art, other drawings can be obtained according to the drawings without creative efforts.

[0027] Figure 1Schematic diagrams showing the effects before and after using the medical dressing provided by the embodiments of the present application; among them Figure 1 (a) Schematic diagram showing the effect of a subject before using the medical dressing provided by some embodiments of the present application; Figure 1 (b) Schematic diagram showing the effect after using the medical dressing provided by some embodiments of the present application. Detailed implementation manners

[0028] In order to make the technical means, creative features, achieved purposes and effects of the present invention easy to understand, the present invention will be further described below in conjunction with specific embodiments.

[0029] In a first aspect, the present application provides a method for preparing a medical composition containing polyglutamic acid, the method comprising:

[0030] Providing a first solution containing purified water, glycerol and carbomer;

[0031] Mixing hydroxyethyl cellulose, polyglutamic acid, trehalose, silicon nitride particles with the first solution under heating conditions to obtain a third mixture;

[0032] Subjecting the third mixture to at least three ultrasonic treatments and cooling to obtain a fourth mixed solution;

[0033] Providing a second solution containing purified water, recombinant human collagen, sodium hyaluronate, β-glucan and benzyl alcohol;

[0034] Mixing the fourth mixed solution with the second solution to obtain a medical composition, and the medical composition includes by mass percentage: sodium hyaluronate: 0.1%-5%, glycerol: 2%-6%, carbomer: 0.35%-0.8%, hydroxyethyl cellulose: 0.3%-3.5%, polyglutamic acid: 0.1%-5%, trehalose: 1.8%-2.5%, recombinant human collagen: 0.1%-1%, benzyl alcohol: 0.5%-1.0%, β-glucan: 0.5%-5.0%, silicon nitride particles: 0.5%-1.5%, and the balance is purified water.

[0035] In the embodiments of the present application, polyglutamic acid is a natural biopolymer material produced by microbial fermentation, having excellent biocompatibility, biodegradability, moisturizing and antibacterial effects; silicon nitride particles have excellent biocompatibility and safety in the medical composition, and at the same time have good antibacterial properties and biological activity; silicon nitride particles have physical pores, reducing the probability of inflammation. Benzyl alcohol is a compound with weak antibacterial properties, which can inhibit the growth of bacteria to a certain extent, reduce the risk of wound infection, and can promote wound healing and tissue repair when acting with recombinant human collagen and β-glucan. Benzyl alcohol is usually used as a solvent to help dissolve and stabilize other whitening active ingredients, such as recombinant human collagen and β-glucan, etc.

[0036] Trehalose in the embodiments of the present application has a certain antioxidant effect, which can reduce the indirect effect of melanin production; recombinant human collagen can repair the skin barrier, improve skin texture and complexion. β-glucan inhibits melanin formation by reducing inflammation, having a certain indirect anti-inflammatory and whitening effect.

[0037] On the basis of promoting wound healing, the medical composition of the present application has a certain whitening effect with the above components.

[0038] Mix hydroxyethyl cellulose, polyglutamic acid, trehalose, silicon nitride particles with the first solution under heating conditions, and the heating temperature can be 60 - 75 °C, which is beneficial to maintaining the dispersion state of each component and improving the uniform mixing degree of each substance.

[0039] In some embodiments, the medical composition includes, by mass percentage: sodium hyaluronate: 4%, glycerol: 4%, carbomer: 0.6%, hydroxyethyl cellulose: 3.5%, polyglutamic acid: 5%, benzyl alcohol: 0.8%, trehalose: 2.0%, recombinant human collagen: 1.0%, β-glucan: 4.0%, silicon nitride particles: 1.0%, and the balance is purified water.

[0040] In some embodiments, the mass ratio of the fourth mixture to the second solution is 1:(0.5 - 2). Controlling the mass ratio of the fourth mixture to the second solution is beneficial to controlling the content of active ingredients in the final medical composition and the uniform dispersion of substances.

[0041] In some embodiments, the mass ratio of polyglutamic acid, β-glucan and silicon nitride particles is 5:4:(0.8 - 1). Controlling the mass ratio of polyglutamic acid, β-glucan and silicon nitride particles within the above range can enable the medical composition to have a certain whitening effect on the basis of promoting wound healing, and can also improve the stability of the medical composition.

[0042] In some embodiments, the medical composition is a solvent type.

[0043] In some embodiments, hydroxyethyl cellulose, polyglutamic acid, trehalose, silicon nitride particles and a first solution are mixed under the condition of heating to 25°C - 40°C to obtain a third mixture.

[0044] In some embodiments, a fourth mixture and a second solution are mixed under the condition of 25°C - 40°C.

[0045] In some embodiments, at least three ultrasonic treatments sequentially include: a first ultrasonic treatment, a second ultrasonic treatment, and a third ultrasonic treatment; the temperature of the first ultrasonic treatment is 40 - 50°C, and ultrasonic dispersion and emulsification are performed at a frequency of 30 - 50 kHz for 1 - 3 min; the temperature of the second ultrasonic treatment is 50 - 60°C, and ultrasonic dispersion and emulsification are performed at a frequency of 20 - 25 kHz for 2 - 5 min; the temperature of the third ultrasonic treatment is 50 - 65°C, and ultrasonic dispersion and emulsification are performed at a frequency of 10 - 15 kHz for 2 - 5 min.

[0046] In some embodiments, the third mixture is subjected to at least three ultrasonic treatments and cooling to obtain a fourth mixture, including:

[0047] The third mixture is subjected to at least three ultrasonic treatments, and then vacuum is turned on for defoaming, and the defoaming time is 3 - 10 min;

[0048] Then, it is cooled to 25 - 30°C to obtain a fourth mixture.

[0049] In some embodiments, the viscosity of the fourth mixture is 100 - 600 cst. Controlling the viscosity of the fourth mixture within the above range can control the content of the active ingredient therein, which is beneficial to intuitively determining the stability and quality of the solution and is beneficial to improving the use effect of the medical composition.

[0050] In a second aspect, the present application provides a medical composition containing polyglutamic acid, which is prepared by the preparation method of the first aspect.

[0051] The above-mentioned medical composition is solvent-based, convenient to use, and has a fresh feeling.

[0052] In a third aspect, the present application provides a medical dressing, which is prepared by drying the medical composition prepared by the preparation method of the first aspect. The medical dressing is in a gel state, and the water content of the medical dressing is 40% - 60%.

[0053] After drying the prepared medical composition, the water content of the medical dressing is 40% - 60%. At this time, it is in a gel state and can be directly applied to the affected area in the form of a dressing, which is beneficial to promoting wound healing and has a certain whitening effect. Example 1

[0054] This embodiment provides a method for preparing a medical composition. The medical composition contains the following components in the following parts by mass: sodium hyaluronate: 4 parts, glycerol: 4 parts, carbomer: 0.6 part, hydroxyethyl cellulose: 3.5 parts, polyglutamic acid: 5 parts, trehalose: 2.0 parts, recombinant human collagen: 1.0 part, β-glucan: 4.0 parts, silicon nitride particles: 1.0 part, benzyl alcohol: 0.8 part, purified water: up to 100 parts. The preparation process is as follows:

[0055] (1) Solution preparation:

[0056] Preparation 1: Take 1% of the purified water, heat and disinfect it, and then cool it to room temperature for standby;

[0057] Preparation 2: Reserve 0.5 KG of water, heat and disinfect it, and then cool it for standby. Use it as needed in the preparation process, such as for flushing the residual raw materials in the container, etc.;

[0058] Preparation 3: Add 2% of the purified water, heat and disinfect it, and then cool it to room temperature. Then add recombinant human collagen and dissolve it completely for standby;

[0059] Preparation 4: Add 1% of the purified water, heat and disinfect it, and then cool it to room temperature. Then add β-glucan and dissolve it completely for standby;

[0060] (2) Add the purified water and glycerol into the water pot. Add carbomer-940 and soak until it is wet, then stir and heat to 75 °C, stir and dissolve, and keep warm for 20 min to obtain the first solution;

[0061] (3) Add hydroxyethyl cellulose, polyglutamic acid, trehalose, and silicon nitride particles into the pot in sequence, mix them with the first solution, and heat and stir to dissolve. Then raise the temperature to 40 °C and keep warm for 20 min;

[0062] (4) Pump the raw materials in the water pot into the emulsifying pot, homogenize at low speed for 3 min. Under the condition of rapid stirring, pump the oil phase into the emulsifying pot, turn on the ultrasonic wave, and perform three ultrasonic treatments in sequence. The temperature of the first ultrasonic treatment is 45 °C, and ultrasonic disperse and emulsify for 2 min at a frequency of 40 kHz; the temperature of the second ultrasonic treatment is 60 °C, and ultrasonic disperse and emulsify for 3 min at a frequency of 23 kHz; the temperature of the third ultrasonic treatment is 65 °C, and ultrasonic disperse and emulsify for 4 min at a frequency of 12 kHz. At this time, the viscosity of the mixed liquid is 450 cst.

[0063] (5) Turn on the cooling water, cool down to 45 °C, turn off the vacuum, add Preparation 1, then turn on the vacuum and stir for 20 min;

[0064] (6) The second solution of purified water, recombinant human collagen, sodium hyaluronate, β-glucan, and benzyl alcohol.

[0065] (7) Cool down to 40°C, turn off the vacuum, add Preparations 3 and 4, then turn on the vacuum again. Stir while cooling down to 38°C for 40 minutes. Cool to 25°C and mix with the second solution. Finish the preparation, transfer to a pot for filling to obtain the medical composition.

[0066] This example provides a method for preparing a medical dressing, including: drying the medical composition to make the water content of the medical composition 50% to form a gel-like medical dressing.

[0067] Example 2

[0068] The difference between this example and Example 1 lies in: different components of the medical composition. The medical composition includes, by mass:

[0069] Sodium hyaluronate: 4 parts, glycerol: 2 parts, carbomer: 0.35 part, hydroxyethyl cellulose: 3 parts, polyglutamic acid: 4.5 parts, trehalose: 2.5 parts, recombinant human-derived collagen: 1.0 part, β-glucan: 0.5 part, silicon nitride particles: 0.5 part, benzyl alcohol: 0.5 part, purified water: added to 100 parts.

[0070] Example 3

[0071] The difference between this example and Example 1 lies in: different components of the medical composition. The medical composition includes, by mass:

[0072] Sodium hyaluronate: 4 parts, glycerol: 6 parts, carbomer: 0.8 part, hydroxyethyl cellulose: 2.5 parts, polyglutamic acid: 3 parts, trehalose: 2.5 parts, recombinant human-derived collagen: 0.29 part, β-glucan: 5.0 parts, silicon nitride particles: 1.5 parts, benzyl alcohol: 1.0 part, purified water: added to 100 parts.

[0073] Example 4

[0074] The difference between this example and Example 1 lies in: different components of the medical composition. The medical composition includes, by mass:

[0075] Sodium hyaluronate: 4 parts, glycerol: 4 parts, carbomer: 0.6 part, hydroxyethyl cellulose: 3.0 parts, polyglutamic acid: 5 parts, trehalose: 2.0 parts, recombinant human-derived collagen: 1.0 part, β-glucan: 4.0 parts, silicon nitride particles: 1.0 part, benzyl alcohol: 1 part, purified water: added to 100 parts.

[0076] Example 5

[0077] The difference between this example and Example 1 lies in: different components of the medical composition. The medical composition includes, by mass:

[0078] Sodium hyaluronate: 4 parts, glycerol: 4 parts, carbomer: 0.6 part, hydroxyethyl cellulose: 2.5 parts, polyglutamic acid: 5 parts, trehalose: 2.0 parts, recombinant human collagen: 1.0 part, β-glucan: 4.0 parts, silicon nitride particles: 1.0 part, benzyl alcohol: 0.5 part, purified water: up to 100 parts.

[0079] Example 6

[0080] The difference between this example and Example 1 lies in: different ultrasonic treatment processes. The temperature of the first ultrasonic treatment is 40 °C, and ultrasonic dispersion emulsification is carried out at a frequency of 50 kHz for 2 min; the temperature of the second ultrasonic treatment is 55 °C, and ultrasonic dispersion emulsification is carried out at a frequency of 20 kHz for 3 min; the temperature of the third ultrasonic treatment is 60 °C, and ultrasonic dispersion emulsification is carried out at a frequency of 10 kHz for 4 min. At this time, the viscosity of the mixed solution is 290 cst.

[0081] Example 7

[0082] The difference between this example and Example 1 lies in: the temperature of the first ultrasonic treatment is 50 °C, and ultrasonic dispersion emulsification is carried out at a frequency of 30 kHz for 2 min; the temperature of the second ultrasonic treatment is 55 °C, and ultrasonic dispersion emulsification is carried out at a frequency of 25 kHz for 4 min; the temperature of the third ultrasonic treatment is 65 °C, and ultrasonic dispersion emulsification is carried out at a frequency of 10 - 15 kHz for 2 min. At this time, the viscosity of the mixed solution is 314 cst.

[0083] Comparative Example 1

[0084] The difference between this comparative example and Example 1 lies in: different components of the medical composition, and the medical composition does not contain polyglutamic acid.

[0085] Comparative Example 2

[0086] The difference between this comparative example and Example 1 lies in: different components of the medical composition, and the medical composition does not contain recombinant human collagen and silicon nitride particles.

[0087] Comparative Example 3

[0088] The difference between this comparative example and Example 1 lies in: different components of the medical composition, the medical composition does not contain benzyl alcohol, and an equal mass of glycerol is used instead.

[0089] Comparative Example 4

[0090] The difference between this comparative example and Example 1 lies in: the frequency is 15 kHz in the first, second, and third ultrasonic treatments, and other steps are the same as in Example 1. At this time, the viscosity of the mixed solution is 510 cst.

[0091] Comparative Example 5

[0092] The difference between this comparative example and Example 1 is as follows: Ethyl cellulose, polyglutamic acid, sodium hyaluronate, trehalose, and silicon nitride particles were successively added to a pot and mixed with the first solution, then heated and stirred to dissolve. The temperature was raised to 80 °C for mixing. The temperature of the second ultrasonic treatment was 80 °C, and the third ultrasonic treatment was carried out at 80 °C. At this time, the viscosity of the mixed solution was 590 cst.

[0093] Test Part

[0094] 1) Stability test:

[0095] The medical dressings obtained in Examples 1-7 and Comparative Examples 1-5 were tested for stability in a high-temperature and high-humidity environment. The samples were placed in an environment with a temperature of 65 °C and a humidity of 75%, and the experiments of the dressings were observed and recorded. The medical dressings obtained in Examples 1-7 had high stability in the high-temperature and high-pressure environment. No delamination occurred within 90 days, and some samples did not even delaminate within 120 days. However, in Comparative Examples 1-5, the dispersion and emulsification were insufficient, and delamination occurred around 60 days. The results are shown in Table 1.

[0096] Through experiments, the medical dressings obtained in Examples 1-7 had high stability in the high-temperature and high-pressure environment. No delamination occurred within 90 days, and some samples did not even delaminate within 120 days. However, in Comparative Examples 1-5, the dispersion and emulsification were insufficient, and delamination occurred around 60 days.

[0097] 2) Moisture retention capacity test:

[0098] Take 10 g of each of the medical dressing samples prepared in Examples 1-7 and Comparative Examples 1-5 and place them in a petri dish, denoted as m0. Expose them to the air at room temperature for a period of time, and weigh the sample masses at 6 h, 12 h, 24 h, and 72 h respectively, denoted as mt. The percentage data of mt / m0 are shown in Table 1.

[0099] 3) Particle size and stability test:

[0100] The medical dressings prepared in the examples and comparative examples were evaluated. Take an equal amount of the medical dressing and place it in a 100 ml sample tube, and place the sample tube in an oven at 59 °C for an accelerated experiment. Use a laser particle size analyzer to examine the changes in the gel-state particle size (D99, μm) and state.

[0101] The test results are shown in Table 1.

[0102] Table 1

[0103]

[0104] As can be seen from the tabular data, the medical dressing obtained by this method has excellent stability. However, in the comparative example under heating acceleration conditions, the particle size of the medical dressing remains stable and has a good moisturizing effect. This also shows that the mixture of this medical dressing forms a gel, which can be stabilized at the nanoscale by appropriately controlling the conditions and has a certain stability.

[0105] After 15 days of using the medical dressing of Example 1 by the subject in the initial state and detected by a micro A skin detector scanner, the results are as Figure 1 shown. Among them, the darker the color and the more red areas, it indicates a poor healing effect. If the healing effect is good, the color is lighter. Figure 1 (a) shows the initial situation without using the medical dressing of Example 1, Figure 1 (b) shows the situation after 15 days of using the medical dressing of Example 1, indicating that the medical dressing of this application has a certain whitening and healing effect.

[0106] The above shows and describes the basic principles, main features and advantages of the present invention. Those skilled in the art of this industry should understand that the present invention is not limited by the above embodiments. What is described in the above embodiments and the specification only illustrates the principles of the present invention. Without departing from the spirit and scope of the present invention, the present invention will have various changes and improvements, and these changes and improvements all fall within the scope of the present invention claimed. The scope of protection claimed by the present invention is defined by the appended claims and their equivalents.

Claims

1. A method for preparing a medical composition containing polyglutamic acid, characterized in that, The method includes: providing a first solution containing purified water, glycerol and carbomer; mixing hydroxyethyl cellulose, polyglutamic acid, trehalose, silicon nitride particles with the first solution under heating conditions to obtain a third mixture, wherein the silicon nitride particles have physical pores; subjecting the third mixture to at least three ultrasonic treatments and cooling to obtain a fourth mixed solution, and the viscosity of the fourth mixed solution is 100 - 450 cst; providing a second solution containing purified water, recombinant human collagen, sodium hyaluronate, β - glucan and benzyl alcohol; mixing the fourth mixed solution with the second solution to obtain the medical composition, and the medical composition includes, by mass percentage: sodium hyaluronate: 0.1% - 5%, glycerol: 2% - 6%, carbomer: 0.35% - 0.8%, hydroxyethyl cellulose: 0.3% - 3.5%, polyglutamic acid: 0.1% - 5%, trehalose: 1.8% - 2.5%, recombinant human collagen: 0.1% - 1%, benzyl alcohol: 0.5% - 1.0%, β - glucan: 0.5% - 5.0%, silicon nitride particles: 0.5% - 1.5%, and the balance is purified water.

2. The preparation method according to claim 1, characterized in that, The medical composition includes, by mass percentage: sodium hyaluronate: 4%, glycerol: 4%, carbomer: 0.6%, hydroxyethyl cellulose: 3.5%, polyglutamic acid: 5%, benzyl alcohol: 0.8%, trehalose: 2.0%, recombinant human collagen: 1.0%, β - glucan: 4.0%, silicon nitride particles: 1.0%, and the balance is purified water.

3. The preparation method according to claim 1, characterized in that, The mass ratio of the fourth mixed solution to the second solution is 1:(0.5 - 2).

4. The preparation method according to claim 1, characterized in that, The mass ratio of the polyglutamic acid, the β - glucan and the silicon nitride particles is 5:4:(0.8 - 1).

5. The preparation method according to claim 1, wherein The medical composition is a solvent type.

6. The preparation method according to claim 1, characterized in that, The at least three ultrasonic treatments sequentially include: the first ultrasonic treatment, the second ultrasonic treatment and the third ultrasonic treatment; the temperature of the first ultrasonic treatment is 40 - 50°C, and ultrasonic dispersion emulsification is carried out at a frequency of 30 - 50 kHz for 1 - 3 min; the temperature of the second ultrasonic treatment is 50 - 60°C, and ultrasonic dispersion emulsification is carried out at a frequency of 20 - 25 kHz for 2 - 5 min; the temperature of the third ultrasonic treatment is 50 - 65°C, and ultrasonic dispersion emulsification is carried out at a frequency of 10 - 15 kHz for 2 - 5 min.

7. The preparation method according to claim 1, characterized in that, Subjecting the third mixture to at least three ultrasonic treatments and cooling to obtain a fourth mixed solution includes: subjecting the third mixture to at least three ultrasonic treatments, then starting vacuum for defoaming, and the defoaming time is 3 - 10 min; then cooling down to 25 - 30°C to obtain a fourth mixed solution.

8. A medical composition containing polyglutamic acid, characterized in that, Prepared by the preparation method according to any one of claims 1 to 7.

9. A medical dressing, characterized in that, Drying the medical composition prepared by the preparation method according to any one of claims 1 to 7, the medical dressing is in a gel state, and the water content of the medical dressing is 40% - 60%.

Images